Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

1. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis

NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis 29928924 2018 08 22 1097-6825 2018 Jun 19 The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. S0091-6749(18)30863-7 10.1016/j.jaci.2018.06.010 Chronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs (...) ). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation. We sought to assess whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outcomes. Patients (n = 323) 18 years and older with moderate-to-severe congestion and NPs were randomized to twice-daily EDS-FLU (93, 186, or 372 μg) or exhalation delivery system (EDS)-placebo for 24 weeks (16 double-blind plus 8 open

EvidenceUpdates2018

2. Fluticasone

Fluticasone Top results for fluticasone - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluticasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma

Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma Abbreviated Submission fluticasone propionate/ formoterol fumarate 50microgram/5microgram, 125microgram/5microgram pressurised inhalation, suspension (Flutiform k-haler ® ) SMC2016 Napp Pharmaceuticals Ltd 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/ formoterol fumarate (Flutiform k-haler ® ) is accepted for use within NHS Scotland. Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting ß 2-agonist (LABA)] is appropriate: • For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting ß2- agonist or • For patients already adequately controlled

Scottish Medicines Consortium2018

5. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk 28737971 2018 01 24 1535-4970 197 1 2018 Jan 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. 47-55 10.1164/rccm.201610-2086OC Many (...) patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease. In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated whether the inhaled corticosteroid fluticasone furoate (FF; 100 μg), the long-acting β-agonist vilanterol (VI; 25 μg), or their combination (FF/VI) modified the rate of decline

EvidenceUpdates2018

6. Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 12 February 2018 Product Update fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy ® Ellipta ® ) SMC No 1303/18 GlaxoSmithKline UK 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment (...) of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy ® Ellipta ® ) is accepted for restricted use within NHS Scotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated

Scottish Medicines Consortium2018

7. fluticasone furoate/vilanterol (Breo Ellipta )

fluticasone furoate/vilanterol (Breo Ellipta ) fluticasone furoate/vilanterol | CADTH.ca Find the information you need fluticasone furoate/vilanterol fluticasone furoate/vilanterol Last Updated: May 31, 2017 Result type: Reports Project Number: SR0524-000 Product Line: Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: Chronic Obstructive Pulmonary Disease (COPD) Submission Type: Resubmission Project Status: Pending Call

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2017

8. fluticasone propionate / salmeterol xinafoate (RespiClick)

fluticasone propionate / salmeterol xinafoate (RespiClick) fluticasone propionate / salmeterol xinafoate | CADTH.ca Find the information you need fluticasone propionate / salmeterol xinafoate Generic Name: fluticasone propionate / salmeterol xinafoate Brand Name: RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New Combination Project Status: Pending Call For Patient Input: September 5, 2017 Patient Input Closed: October 25, 2017 Anticipated Date: October 3

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2017

9. fluticasone propionate (RespiClick)

fluticasone propionate (RespiClick) fluticasone propionate | CADTH.ca Find the information you need fluticasone propionate Generic Name: fluticasone propionate Brand Name: RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New Project Status: Pending Call For Patient Input: September 5, 2017 Patient Input Closed: October 25, 2017 Anticipated Date: October 3, 2017 Biosimilar: No Fee Schedule 1 : Pending Follow us: © 2017 Canadian Agency for Drugs

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2017

10. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. BACKGROUND: Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice. METHODS: We did an open-label, randomised, controlled, two-arm effectiveness trial at 74 general practice clinics in Salford (...) and South Manchester, UK. Patients aged 18 years or older with a general practitioner's diagnosis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treatment with a once-daily inhaled combination of either 100 μg or 200 μg fluticasone furoate with 25 μg vilanterol or optimised usual care and followed up for 12 months. The primary endpoint was the percentage of patients who achieved an asthma control test (ACT) score of 20 or greater or an increase in ACT score

Lancet2017

11. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study 27492833 2016 08 05 2016 10 03 1399-3003 48 4 2016 Oct The European respiratory journal Eur. Respir. J. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. 1030-1039 10.1183/13993003.00216-2016 The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable (...) , moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone 50/500 µg twice-daily via Accuhaler. The primary end-point was peak forced expiratory volume in 1 s (FEV1) at week 24. Other end-points included Transition Dyspnoea Index

EvidenceUpdates2016

12. Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma

Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma 27622699 2016 09 13 2017 05 17 2017 05 17 1097-6833 178 2016 Nov The Journal of pediatrics J. Pediatr. Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma. 246-253.e2 S0022-3476(16)30669-2 10.1016/j.jpeds.2016.08.010 To evaluate the dose-response, efficacy, and safety of fluticasone furoate (FF; 25 µg, 50 µg, and 100 µg), administered once daily (...) in the evening during a 12-week treatment period to children with inadequately controlled asthma. This was a Phase IIb, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, placebo- and active-controlled study in children aged 5-11 years with inadequately controlled asthma. The study comprised a 4-week run-in period, 12-week treatment period, and 1-week follow-up period. Children were randomized to receive either placebo once daily, fluticasone propionate (FP) 100 µg twice daily

EvidenceUpdates2016

13. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. BACKGROUND: Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice. METHODS: In a controlled effectiveness trial conducted in 75 general practices, we (...) randomly assigned 2799 patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group). The primary outcome was the rate of moderate or severe exacerbations among patients who had had an exacerbation within 1 year before the trial. Secondary outcomes were the rates of primary care contact (contact with a general practitioner, nurse, or other health care

NEJM2016

14. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. BACKGROUND: Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination (...) in children. METHODS: We randomly assigned, in a 1:1 ratio, children 4 to 11 years of age who required daily asthma medications and had a history of asthma exacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization), as assessed in a time-to-event analysis. The statistical design specified that noninferiority would be shown

NEJM2016

15. Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

European Medicines Agency - EPARs2016

17. Vilanterol and fluticasone furoate for asthma.

Vilanterol and fluticasone furoate for asthma. BACKGROUND: Vilanterol (VI) is a long-acting beta 2 -agonist (LABA) that binds to the beta 2 -adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the commonly used LABAs licensed for use in asthma (...) participants, of whom 5638 completed the study. All studies lasted between two and 78 weeks and showed good methodological quality overall.We included 10 comparisons in this review, seven for which the dose of VI and FF was 100/25 mcg (VI/FF 100/25 mcg vs placebo; VI/FF 100/25 mcg vs same dose of FF; VI/FF 100/25 mcg vs same dose of VI; VI/FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice-daily; VI/FF 100/25 mcg vs fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice-daily; VI/FF 100/25 mcg

Cochrane2016

18. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear. METHODS: We conducted a 52-week, randomized, double-blind, double (...) -dummy, noninferiority trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations. RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium

NEJM2016

19. Safety of Fluticasone plus Salmeterol in Asthma - Reassuring Data, but No Final Answer.

Safety of Fluticasone plus Salmeterol in Asthma - Reassuring Data, but No Final Answer. Safety of Fluticasone plus Salmeterol in Asthma--Reassuring Data, but No Final Answer. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 26946980 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 12;374(19):1887-8. doi: 10.1056/NEJMe1601040. Epub 2016 Mar 6. Safety of Fluticasone plus Salmeterol in Asthma--Reassuring Data, but No Final Answer. 1 . 1 From the Arizona Respiratory Center, University of Arizona, Tucson. Comment on [N Engl J Med. 2016

NEJM2016

20. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. BACKGROUND: The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS (...) : In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related

NEJM2016